People · Operator

Peter J. Clare

Named in public records as an officer, director or promoter · active 2012–2012 · Pharmaceuticals

1
Companies
1
Filings
$1.3M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Jaguar Holding Co IPharmaceuticalsSeed$1.3M$47.6M2012
Operator network

Peter J. Clare at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

B. Judd Hartman · 3 companies · 1 sharedB. Judd HartmanDaniel G. Darazsdi · 2 companies · 1 sharedDaniel G. DarazsdiJeffrey J. Kindler · 2 companies · 1 sharedJeffrey J. KindlerP Hunter Philbrick · 2 companies · 1 sharedP Hunter PhilbrickStephen H. Wise · 2 companies · 1 sharedStephen H. WiseWilliam J. Sharbaugh · 2 companies · 1 sharedWilliam J. Sharba…Allen Hunter Thorpe · 1 companies · 1 sharedAllen Hunter Thor…Brian G. Tuttle · 1 companies · 1 sharedBrian G. TuttleCharles Hunter Rozwat · 1 companies · 1 sharedCharles Hunter Ro…David Simmons · 1 companies · 1 sharedDavid SimmonsKaren Hunter Bechtel · 1 companies · 1 sharedKaren Hunter Bech…Martin J. Madaus · 1 companies · 1 sharedMartin J. MadausRobert J. Essner · 1 companies · 1 sharedRobert J. EssnerJaguar Holding Co I · $1.3M raisedJaguar Holding Co IPeter J. ClarePC
Peter J. Clare Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Peter J. Clare on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
B. Judd Hartman13
Stephen H. Wise12
Daniel G. Darazsdi12
William J. Sharbaugh12
P Hunter Philbrick12
Jeffrey J. Kindler12
Brian G. Tuttle11
Martin J. Madaus11
Allen Hunter Thorpe11
Charles Hunter Rozwat11
Karen Hunter Bechtel11
Robert J. Essner11
David Simmons11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.